10-Q: eXoZymes Reports Q2 2026 Results, Faces Going Concern Doubt

eXoZymes Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational cash burn, leading to substantial doubt about its ability to continue as a going concern.

Summary

• eXoZymes Inc. reported its financial results for the quarter and six months ended June 30, 2026.
• The company incurred net losses of $2,878,614 for the three months and $5,248,861 for the six months ended June 30, 2026.
• Operating costs increased by 15.9% for the three-month period and 18.7% for the six-month period compared to the prior year.
• Cash and cash equivalents increased significantly to $5,652,696 as of June 30, 2026, primarily due to net proceeds from equity offerings.
• Despite the capital infusion, management has concluded there is substantial doubt about the company's ability to continue as a going concern due to ongoing operating cash burn.
• The company is actively pursuing non-dilutive funding, additional offerings, and potential financing or licensing of intellectual property.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the continued net losses, significant cash burn, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, despite recent capital raises.

Positives

• Significant increase in cash and cash equivalents to $5,652,696 as of June 30, 2026, from $3,039,343 as of December 31, 2025, largely due to successful equity offerings.
• Net proceeds of $5,861,147 were raised from underwritten public and registered direct offerings in June 2026.
• Working capital increased to $4,550,841 as of June 30, 2026, from $2,372,687 as of December 31, 2025.
• Professional fees decreased by 45.3% for the six-month period, indicating improved cost management in certain areas.
• The company secured a key industrial partnership with a $3 million share of a $9.2 million grant from the U.S. National Science Foundation (NSF) on July 1, 2025.

Negatives

• The company incurred substantial net losses: $2,878,614 for the three months and $5,248,861 for the six months ended June 30, 2026.
• Operating costs increased by 15.9% for the three-month period and 18.7% for the six-month period, outpacing revenue (which is zero).
• Research and development costs increased significantly by 85.7% for the six-month period.
• There is substantial doubt about the company's ability to continue as a going concern due to its operating cash burn and insufficient working capital to fund operations for the next twelve months.
• A warrant liability of $1,902,612 was recognized as of June 30, 2026, related to recent equity offerings.
• Grants receivable decreased by 61.1% to $201,256 as of June 30, 2026, from $517,359 as of December 31, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to its operating cash burn and insufficient working capital.
• The company's ability to continue operations and meet long-term obligations depends on securing additional financial resources or achieving profitable operations.
• Changes to United States tariff and import/export regulations may adversely affect the business, financial condition, and results of operations.
• Government actions on tariffs, trade policies, immigration, and research grants could impede the company's ability to conduct research and raise capital.
• The company's endeavors to create and bring new technologies to market may never come to fruition or reach commercial viability.
• Technologies developed may not gain widespread or timely acceptance, or may fail to receive necessary regulatory approvals.

Future Outlook

The company's ability to continue operations and meet its long-term obligations is dependent on securing additional financial resources or achieving profitable operations. Management is pursuing non-dilutive funding, additional offerings, and potential financing or licensing of intellectual property. There is substantial doubt about the company's ability to continue as a going concern.

Management Comments

• Management believes that eXoZymes technology is a differentiated and unique synthetic biology platform that will enable scalable production of chemical molecules found in nature.
• Management believes the platform will enable scalable production of chemical molecules found in nature in a process that is alternative to and more environmentally friendly and sustainable than typical methods.
• Management believes that inflation has not had a material effect on its operations to date, other than its impact on the general economy.
• Management does not believe supply chain issues will have a significant impact on its business activities currently or in the near future.
• Management is continuing to monitor potential recessionary indicators and will adjust business and financing plans as more information becomes available.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that eXoZymes operates in the highly competitive and capital-intensive biotechnology sector, where significant investment in R&D is required. The company's pre-revenue status and reliance on grants and equity financing are common for early-stage biotech firms, but the explicit going concern warning highlights the inherent risks in this industry.

Comparison to Industry Standards

• The net loss of $5,248,861 for the six months ended June 30, 2026, is substantial for a pre-revenue company, but not uncommon in the biotech sector where long development cycles and high R&D costs are typical.
• The company's cash burn of $3,164,719 for the six months ended June 30, 2026, is a critical metric. Many early-stage biotech companies face similar challenges, often relying on frequent capital raises to sustain operations.
• The reliance on government grants (e.g., from NSF, NIH) is a common strategy for biotech firms to offset R&D expenses, though the decrease in grant funding noted in the filing is a concern.
• The significant increase in cash due to equity offerings ($5,861,147 net proceeds) is a positive sign of market confidence, but the concurrent 'going concern' warning tempers this optimism. Companies like Moderna and BioNTech also relied heavily on funding rounds in their early stages.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened litigation that would have a material adverse effect on its business.

Related Party Transactions

• The company had outstanding receivables from MDB Capital Holdings, LLC of $18,616 as of June 30, 2026.
• The company had outstanding payables to MDB Capital Holdings, LLC of $5,330 as of December 31, 2025.
• MDB Capital Holdings, LLC was the underwriter for the underwritten public offering and placement agent for the registered direct offering in June 2026.

Stakeholder Impact

• Shareholders: Continued net losses and the going concern warning pose significant risks to shareholder value. However, recent capital raises provide runway for operations.
• Employees: Increased compensation expenses suggest potential hiring, but the going concern issue may create job security concerns.
• Creditors: The company's ability to meet long-term obligations is uncertain, posing a risk to creditors.
• Government/Grantors: The company must comply with terms of research grants, and any failure could impact funding.

Next Steps

• Continue to pursue non-dilutive funding opportunities, including grants.
• May seek additional offerings under its shelf registration statement.
• May seek institutional or bank financing.
• May pursue the sale or licensing of intellectual property.
• Implement measures to remediate material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company continues to incur significant net losses and has explicitly stated substantial doubt about its ability to continue as a going concern. While recent capital raises provide some liquidity, the fundamental business model has not yet demonstrated profitability, and the ongoing cash burn remains a critical concern. The risks associated with the going concern status and the uncertain path to commercialization outweigh the positives of recent funding.

Keywords

synthetic biology, biotechnology, pre-revenue, going concern, equity offering, research and development, grants, warrant liability